News

/News/

Remap proud to be part of the Northwest Biotech Initiative

Charles Hewitt and Fatima Chunara had a great day on saturday mentoring and supporting the students at the Northwest Biotech Initiative Case Competition, where we were very proud to have sponsored the best speaker prize. Charles Hewitt also gave a great presentation on why he chose a career in consulting and the skills needed to thrive in the industry. #NWBICCC2018 

By | 2018-06-11T12:52:55+00:00 June 11th, 2018|News|0 Comments

Join Remap at the Northwest Biotech Initiative – Saturday 9th June

Remap are extremely proud to be sponsoring the best speaker prize tomorrow at the Northwest Biotech Initiative Annual Consulting Case Competition. Our very own Charlie Hewitt will be talking about Strategic Consultancy within the pharmaceutical industry and how you can become a Consultant. If you are in and around Manchester tomorrow, come and join us!

By | 2018-06-08T14:56:59+00:00 June 8th, 2018|News|0 Comments

How successful has the BEAM Alliance Initiative and biopharma been at addressing Antimicrobial Resistance (AMR)?

The AMR global threat Antimicrobial resistance (AMR) has long been recognised as a global epidemic but it is only relatively recently that it has been accepted by worldwide governments as a global public health crisis and an urgent threat. Today, an estimated 700,000 people die each year because of the growing number of potentially deadly infectious pathogens. These include pathogens that [...]

By | 2018-06-08T09:42:48+00:00 June 7th, 2018|News|0 Comments

Come and see us at the BIO International Convention 4-7 June

Paul Craddy and Graham Foxon are looking forward to attending the #BIOConvention in Boston next week, where they will be networking with biotech and pharma companies who want to identify the potential price and value of their asset, from a payer perspective.  Drop us a line if you are attending the event and wish to discuss any pricing or market access challenges you [...]

By | 2018-06-08T08:46:28+00:00 May 30th, 2018|News|0 Comments

ICERS are not all the same. How cost-effectiveness estimates differ between the UK and US

Is there is a difference between incremental cost-effectiveness ratios (ICERs) in oncology calculated by the Institute for Clinical and Economic Review (ICER) in the US and the National Institute for Health and Care Excellence (NICE) in the UK, and if so, are any differences are solely driven by drug costs. Read our findings here ICERS are not all the same. How [...]

By | 2018-06-08T12:34:52+00:00 May 28th, 2018|Publications|0 Comments

Graham and Paul are looking forward to attending the BIO Convention next week

We had a great few days at ISPOR Baltimore, we are now looking forward to the BIO International Convention in Boston 4-7 June. We are partnering with companies at BIO who want to identify the potential price and value of their asset, from a payer perspective. Drop us a line if you are attending and wish to discuss any market access [...]

By | 2018-06-08T08:46:58+00:00 May 25th, 2018|News|0 Comments

Our ISPOR 2018 Baltimore Poster Abstract is now available to view

ICERS ARE NOT ALL THE SAME. HOW COST-EFFECTIVENESS ESTIMATES DIFFER BETWEEN THE UK AND US OBJECTIVES: To determine if there is a difference between incremental cost-effectiveness ratios (ICERs) in oncology calculated by the Institute for Clinical and Economic Review (ICER) in the US and the National Institute for Health and Care Excellence (NICE) in the UK, and if any differences are [...]

By | 2018-06-08T08:44:41+00:00 May 11th, 2018|News|0 Comments